Business Wire

AFYX Therapeutics Presents New Study Showing Therapeutic Antibody Delivery to Oral Mucosa Using Rivelin Biodegradable Mucoadhesive Patch

SAN DIEGO & COPENHAGEN, Denmark--(BUSINESS WIRE)--AFYX Therapeutics (“AFYX”), a clinical-stage biopharmaceutical company developing innovative approaches to treat mucosal diseases, announced results ...
Business Wire

AFYX Therapeutics Presents Phase 2 Data of Rivelin-CLO at 2021 AAOM Virtual Conference

SAN DIEGO & COPENHAGEN--(BUSINESS WIRE)--AFYX Therapeutics (“AFYX”), a clinical-stage biopharmaceutical company developing innovative approaches to treat mucosal diseases, today announced Phase 2 ...
Business Insider

AFYX Therapeutics Presents Clinical and Preclinical Research on Rivelin Treatment for Mucosal Diseases at 14th Biennial Congress of European Association of Oral Medicine

SAN DIEGO and COPENHAGEN, Denmark, Sept. 27, 2018 /PRNewswire/ -- AFYX Therapeutics (formerly known as Dermtreat), a clinical stage biopharmaceutical company developing innovative approaches to treat ...
Medindia

Dermtreat Announces First Patient Dosed in Phase 2b Clinical Trial of Rivelin Clobetasol for Oral Lichen Planus

SAN DIEGO and COPENHAGEN, Denmark, July 23, 2018 /PRNewswire/ -- Dermtreat, a clinical-stage biopharmaceutical company focused on mucosal diseases, today announced treatment of the first patient in a ...